Click here if you cannot read this message

  Press Release 16 February 2015  

Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015

Gosselies, Belgium, 16 February 2015 - BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and fracture prevention, today announces that it will participate in several key partnering and investor conferences in Europe, the US and Asia.

BIO-Europe Spring 2015, Paris, France
9-11 March - Presenter: Enrico Bastianelli, CEO
KBC Securities Healthcare Conference, Brussels, Belgium
19 March - Participant: Wim Goemaere, CFO
BioPharma Asia Convention 2015, Singapore
23-25 March - Participant: Enrico Bastianelli, CEO
ARM Regen Med Investor Day 2015, New York, USA
25 March - Presenter: Wim Goemaere, CFO
BioTrinity 2015, London, UK
11-13 May - Presenter: Wim Goemaere, CFO
World Stem Cells & Regenerative Medicine Congress 2015, London, UK
20-22 May - Presenter: Enrico Bastianelli, CEO
Knowledge for Growth 2015, Ghent, Belgium
21 May - Presenter: Wim Goemaere, CFO
BIO International Convention 2015, Philadelphia, USA
15-18 June - Participant: Enrico Bastianelli, CEO

Bone Therapeutics will also be represented at several retail events:
Life Sciences Beleggerscongres, Leuven, Belgium
21 March - Participant: Wim Goemaere, CFO
VFB Happening, Brussels, Belgium
25 April - Participant: Wim Goemaere, CFO


To read this press release in French or Dutch, please follow the link below:



For further information, please contact:

Bone Therapeutics SA

Tel: +32 (0)2 529 59 90
Enrico Bastianelli, Chief Executive Officer
Wim Goemaere, Chief Financial Officer

For Belgium and International Media Enquiries:

Consilium Strategic Communications

Amber Bielecka, Mary-Jane Elliott,
Jessica Hodgson and Lindsey Neville
Tel: +44 (0) 20 3709 5708

For French Media and Investor Enquiries:

NewCap Investor Relations & Financial Communications

Pierre Laurent, Antoine Denry
Tel: + 33 (0)1 44 71 94 94


Follow us

Click here to unsubscribe

About Bone Therapeutics

Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products intended for bone fracture repair and fracture prevention. The current standard-of-care in this field involves major surgeries and long recovery periods. To overcome these problems, Bone Therapeutics is developing a range of innovative regenerative products containing osteoblastic/bone-forming cells, administrable via a minimally invasive percutaneous technique; a unique proposition in the market.
PREOB®, Bone Therapeutics’ autologous bone cell product, is currently in pivotal Phase IIb/III clinical studies for two indications: osteonecrosis and non-union fractures, and in Phase II for severe osteoporosis. ALLOB®, its allogeneic “off-the-shelf” bone cell product, is in Phase II for the treatment of delayed-union fractures and lumbar fusion for degenerative disease of the spine. The Company also runs preclinical research programs and develops novel product candidates.
Founded in 2006, Bone Therapeutics is headquartered in Gosselies (South of Brussels, Belgium). Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards and are protected by a rich IP estate covering 9 patent families. Further information is available at

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Bone Therapeutics S.A. • Rue Adrienne Bolland, 8 • 6041 Gosselies • Belgium (Europe) • Phone: +32 (0) 2 529 59 90 • Fax: +32 (0) 2 529 59 93 •